

BPV Case ID _____

Affix BPV Case ID Barcode Label

Tissue Bank ID: _____

Form Completed By: _____

Date Form Was Completed: __/__/_____
 (MM/DD/YYYY)

Lung Slide Pathology Review

1. Slide ID examined by pathologist:

2. Parent specimen ID of the sample from which this slide was derived:

3. Organ of origin:

Select One:
 Lung
 Other (specify)
Specify other organ of origin:

If Other was selected, specify other organ of origin:

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

Date Completed: __/__/____
 MM/DD/YYYY

4. Histologic type:

If Other was selected, record other histologic type:

Select All That Apply:

- Adenocarcinoma of lung, acinar (WHO code: 8550/3)
- Adenocarcinoma of lung, bronchioalveolar (WHO code: 8250/2)
- Adenocarcinoma of lung, bronchioalveolar, mixed nonmucinous and mucinous or indeterminate (WHO code: 8254/3)
- Adenocarcinoma of lung, bronchioalveolar, mucinous (WHO code: 8253/3)
- Adenocarcinoma, of lung, bronchioalveolar, nonmucinous (WHO code: 8252/3)
- Adenocarcinoma of lung, clear cell (WHO code: 8210/3)
- Adenocarcinoma of lung, fetal
- Adenocarcinoma of lung, mixed subtype (specify) (WHO code: 8333/3)

Specify types and %:

- Adenocarcinoma of lung, mucinous (colloidal) (WHO code: 8480/3)
- Adenocarcinoma of lung, mucinous cystadenocarcinoma (WHO code: 8470/3)
- Adenocarcinoma of lung, papillary (WHO code: 8260/3)
- Adenocarcinoma of lung, signet ring (WHO code: 8490/3)
- Adenocarcinoma of lung, solid with mucin production (WHO code: 8230/3)
- Squamous cell carcinoma (WHO code: 8070/3)
 - Papillary variant of squamous cell carcinoma (WHO code: 8052/3)
 - Clear cell variant of squamous cell carcinoma (WHO code: 8084/3)
 - Small cell variant of squamous cell carcinoma (WHO code: 8073/3)
 - Basaloid variant of squamous cell carcinoma (WHO code: 8083/3)
- Other (specify)

Specify other histologic type:

BPV Case ID: _____	Tissue Bank ID: _____
Form Completed By: _____	Date Completed: __/__/____ MM/DD/YYYY

5. Greatest tumor dimension on slide:	_____ (mm)	
6. Percent of cross-sectional surface area of entire slide composed of tumor focus (includes necrotic tumor):	_____ %	
7. Percent of tumor nuclei by cell count of the entire slide (number of tumor epithelial cell nuclei as compared to all cell nuclei):	_____ %	
8. Percent of cross-sectional surface area of entire slide composed of necrotic tissue:	_____ %	

Note: BPV case acceptance criteria require necrosis percentage of <20% of the entire slide AND tumor content of ≥50% tumor nuclei.

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

Date Completed: __/__/____
 MM/DD/YYYY

Histologic Profile Quantitative Assessment of Tumor Should Total 100%

9. Histologic profile quantitative assessment:	Percent viable tumor by surface area (not including stroma)	%	
	Percent necrotic tumor by surface area		
	Percent tumor stroma by surface area		
	Percent non-cellular component by surface area (i.e., mucin, hemorrhage, blood clot, etc.) If present, describe non-cellular component:		
	Histologic profile total % (should equal 100%)		
10. Histologic grade (AJCC 7th edition):	Select One: <input type="radio"/> G1: Well differentiated <input type="radio"/> G2: Moderately differentiated <input type="radio"/> G3: Poorly differentiated <input type="radio"/> G4: Undifferentiated <input type="radio"/> GX: Cannot be assessed		

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

Date Completed: __/__/____
 MM/DD/YYYY

Tumor Staging per AJCC 7th Edition

11. pT: Pathologic spread primary tumor (AJCC 7th edition):

Select One:

- pTX
- pT0
- pTis
- pT1
 - pT1a
 - pT1b
- pT2
 - pT2a
 - pT2b
- pT3
- pT4

12. pN: Pathologic spread lymph nodes (AJCC 7th edition):

Select One:

- pNX
- pN0
- pN1
- pN2
- pN3

13. M: Distant metastases (AJCC 7th edition):

Select One:

- cM0
- cM1
 - cM1a
 - cM1b
- pM1
 - pM1a
 - pM1b

14. Pathologic tumor stage group (AJCC 7th edition):

Select One:

- Occult carcinoma
- Stage 0
- Stage IA
- Stage IB
- Stage IIA
- Stage IIB
- Stage IIIA
- Stage IIIB
- Stage IV

PR-0009-F3

VER. 03.02

Effective Date: 07/16/2014

Page 6 of 7

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

Date Completed: __/__/____
 MM/DD/YYYY

15. Did pathology review of the hematoxylin and eosin slide derived from quality control formalin-fixed paraffin-embedded tumor tissue confirm the histological type to be eligible for BPV study?

Select One:

- Yes
- No

16. This slide meets the microscopic analysis criteria of the BPV project of necrosis percentage of <20% AND tumor content of ≥50% tumor nuclei:

Select One:

- Yes
- No

If No is selected, specify what findings do not meet the microscopic analysis criteria of the BPV project:

17. Pathology review comments:

PR-0009-F3

VER. 03.02

Effective Date: 07/16/2014

Page 7 of 7

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

Date Completed: __/__/____
 MM/DD/YYYY

Concordance With Diagnostic Pathology Report

18. This slide is consistent with the findings of the diagnostic pathology report for this case:

Select One:

Yes

No

If No is selected, specify what findings are not consistent with the diagnostic pathology report:

19. Name of local biospecimen source site reviewing pathologist:

20. Date of slide review by the pathologist:

21. Data entry in the local pathology review form was performed by: